Tamoxifen is a selective estrogen receptor modulator (Jordan and Dowse, 1976) that reduces by half the risk of breast cancer recurrence in early stage patients whose tumor cells express the estrogen receptor (Early Breast Cancer Trialists Collaborative Group, 2005). Here, ESR1 is linked to breast carcinoma.